Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial

Circulation

Volumn 140, Issue 9, 2019, Pages 739-750

  Mahaffey, Kenneth W ^a   Jardine, Meg J ^b,c   Bompoint, Severine ^b   Cannon, Christopher P ^d,i   Neal, Bruce ^b,e,f   Heerspink, Hiddo J L ^b,g   Charytan, David M ^h,i   Edwards, Robert ^j   Agarwal, Rajiv ^k   Bakris, George ^l   Bull, Scott ^j   Capuano, George ^j   De Zeeuw, Dick ^g   Greene, Tom ^m   Levin, Adeera ⁿ   Pollock, Carol ^o   Sun, Tao ^j   Wheeler, David C ^p   Yavin, Yshai ^j   Zhang, Hong ^q   Zinman, Bernard ^r   Rosenthal, Norman ^j   Brenner, Barry M ^i,s   Perkovic, Vlado ^b,t   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

ⁱ HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^j JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^m UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^o UNIVERSITY OF SYDNEY   (Australia)

^p ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^q PEKING UNIVERSITY FIRST HOSPITAL   (China)

^r MOUNT SINAI HOSPITAL   (Canada)

^s HARVARD MEDICAL SCHOOL   (United States)

^t ROYAL NORTH SHORE HOSPITAL   (Australia)

more..

Author keywords

canagliflozin; clinical trial; diabetes mellitus; primary prevention; renal insufficiency, chronic; secondary prevention

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PLACEBO; RENIN INHIBITOR; SULFONYLUREA;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CLINICAL EVALUATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRACTURE; HAZARD RATIO; HEALTH CARE QUALITY; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUMBERS NEEDED TO TREAT; OUTCOME ASSESSMENT; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; UNSTABLE ANGINA PECTORIS; CLINICAL TRIAL; DRUG THERAPY; PATHOLOGY; PLACEBO EFFECT; PROPORTIONAL HAZARDS MODEL; RISK; TREATMENT OUTCOME;

CANAGLIFLOZIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLACEBO EFFECT; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RISK; SECONDARY PREVENTION; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85071325197     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.119.042007     Document Type: Article

References (14)

1. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, de Jong P, Gansevoort RT, van der Velde M, Matsushita K, et al Chronic Kidney Disease Prognosis Consortium Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality: a collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011 79 1341 1352. doi: 10.1038/ki.2010.536
2. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, DECLARE-TIMI 58 Investigators Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019 380 347 357. doi: 10.1056/NEJMoa1812389
3. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 373 2117 2128. doi: 10.1056/NEJMoa1504720
4. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017 377 644 657. doi: 10.1056/NEJMoa1611925
5. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019 393 31 39. doi: 10.1016/S0140-6736(18)32590-X
6. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, CREDENCE Trial Investigators Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019 380 2295 2306. doi: 10.1056/NEJMoa1811744
7. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, James MT, Hemmelgarn BR, Alberta Kidney Disease Network Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012 380 807 814. doi: 10.1016/S0140-6736(12)60572-8
8. Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, CREDENCE Study Investigators The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 2017 46 462 472. doi: 10.1159/000484633
9. Altman DG, Confidence intervals for the number needed to treat. BMJ 1998 317 1309 1312. doi: 10.1136/bmj.317.7168.1309
10. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B, EMPA-REG OUTCOME Investigators Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016 375 323 334. doi: 10.1056/NEJMoa1515920
11. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Bansilal S, Bhatt DL, Leiter LA, The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J 2018 200 83 89. doi: 10.1016/j.ahj.2018.01.012
12. Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, CANVAS Program Collaborative Group Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018 137 323 334. doi: 10.1161/CIRCULATIONAHA.117.032038
13. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI, Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 2017 136 1643 1658. doi: 10.1161/CIRCULATIONAHA.117.030012
14. American Diabetes Association Standards of medical care in diabetes-2019. Diabetes Care 2019 42 S7 S12